<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978235</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-4464-101</org_study_id>
    <nct_id>NCT02978235</nct_id>
  </id_info>
  <brief_title>A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma</brief_title>
  <official_title>A Phase 1, Open-Label Safety, Pharmacokinetic and Efficacy Study of TAS4464 in Patients With Multiple Myeloma or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1 portion of this study will determine the safety of TAS4464 and the most&#xD;
      appropriate dose for patients with Multiple Myeloma or Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial was put on Clinical Hold prior to Phase 2 due to cases of drug induced liver injury&#xD;
      meeting the criteria for Hy's Law.&#xD;
&#xD;
      Background and Rationale:&#xD;
&#xD;
      â€¢ TAS4464 is an investigational NEDD8 activating enzyme (NAE) inhibitor, a compound which may&#xD;
      affect cancer cell growth and survival. Thus, TAS4464 may help in the treatment of cancer.&#xD;
&#xD;
      Phase 1:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
        -  To investigate the safety and tolerability of TAS4464&#xD;
&#xD;
        -  To identify a tolerated dose of TAS4464&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To investigate the preliminary efficacy of TAS4464&#xD;
&#xD;
        -  To investigate the pharmacokinetics (PK) and the pharmacogenomics (PGx) of TAS4464&#xD;
&#xD;
        -  To investigate the pharmacodynamics of TAS4464&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was put on Clinical Hold and subsequently terminated prior to Phase 2 due to cases of&#xD;
    drug induced liver injury meeting the criteria for Hy's Law&#xD;
  </why_stopped>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing any dose-limiting toxicities, during dose escalation period, to determine maximum tolerated dose of TAS4464, using NCI CTCAE criteria, laboratory testing, performance status assessments, and other routine visit procedures</measure>
    <time_frame>Completion of Cycle 1 (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of TAS4464, defined as Objective Response Rate (ORR) per IWG criteria (NHL) and IMWG criteria (MM). This will take into consideration routine assessments including: imaging scans, physical exams, blood tests, urine tests and biopsy results</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>NonHodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>TAS4464</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS4464</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>TAS4464</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent&#xD;
&#xD;
          2. Women of child-bearing potential must have a negative pregnancy test&#xD;
&#xD;
        Multiple Myeloma:&#xD;
&#xD;
        Confirmed diagnosis of Multiple Myeloma with measurable disease, having been treated with&#xD;
        at least two prior lines of therapy.&#xD;
&#xD;
        Lymphoma:&#xD;
&#xD;
        Confirmed diagnosis of Non-Hodgkin Lymphoma with measurable disease, having been treated&#xD;
        with at least one anthracycline-based therapy, with relapse or progression since the last&#xD;
        treatment received.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following treatments, within the specified time frame, prior to the first&#xD;
             dose of TAS4464:&#xD;
&#xD;
               1. Major surgery within 28 days&#xD;
&#xD;
               2. Radiation/chemotherapy within 21 days&#xD;
&#xD;
               3. Monoclonal antibodies within 28 days&#xD;
&#xD;
               4. Corticosteroid administration &gt;20 mg/day of prednisone or equivalent within 14&#xD;
                  days&#xD;
&#xD;
               5. Proteasome inhibitors within 14 days&#xD;
&#xD;
               6. Immunomodulatory agents within 7 days&#xD;
&#xD;
               7. Stem cell transplant within 3 months&#xD;
&#xD;
               8. Current immunosuppressive treatment for graft versus host disease&#xD;
&#xD;
               9. Current use of an investigational agent&#xD;
&#xD;
          2. Active graft versus host disease&#xD;
&#xD;
          3. Known serious illness or medical condition&#xD;
&#xD;
          4. Prior treatment with TAS4464 or known hypersensitivity to any of its inactive&#xD;
             ingredients or drugs similar in class&#xD;
&#xD;
          5. Pregnant or breast-feeding female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack Meridian Health</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>MCL</keyword>
  <keyword>Peripheral T-Cell Lymphoma</keyword>
  <keyword>PTCL</keyword>
  <keyword>TAS4464</keyword>
  <keyword>NEDD8</keyword>
  <keyword>NAE inhibitor</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

